order to minimize treatment-related hepatotoxicity, 8, 9 which may contribute to the lower cure rates for adults with ALL. Therefore, studies that can elucidate the mechanism of drug-induced hepatotoxicity during the treatment of ALL may lead to therapeutic strategies that can reduce the frequency of hepatotoxicity, identify patients who are most likely to benefit from treatment, and possibly improve cure rates by reducing treatment interruptions due to hepatotoxicity.
We investigated coding and noncoding genetic variants associated with the elevation of alanine aminotransferase (ALT) after remission induction therapy. A total of 715 St. Jude Children's Research Hospital patients were evaluable with genotyping and postinduction chemotherapy ALT levels. We tested for replication in 2,285 patients treated on the Children's Oncology Group (COG) AALL0232 trial.
RESULTS
Patients enrolled on St. Jude Children's Research Hospital (SJCRH) Total XV or Total XVI received similar induction therapy, with a few notable differences ( Table 1 ). The Total XV protocol included native E. coli asparaginase (Elspar), whereas the Total XVI protocol used PEGylated E. coli asparaginase (Oncaspar). Patients enrolled on Total XV received mercaptopurine, whereas most on Total XVI received thioguanine; those on Total XV received preinduction window therapy with methotrexate, whereas those on Total XVI did not ( Table 1) . In both protocols, patients with higher minimal residual disease (MRD) at day 15-19 of induction received additional asparaginase compared to those without.
Overall, 715 patients were evaluable for postinduction ALT data in the discovery cohort (Table 2, Figure S1 ). By univariate analysis (Table S1) 
, and gender were associated with postinduction ALT levels. In multivariate analysis (Table 3) , higher ALT levels were associated with Total XVI treatment protocol (P 5 0.041), receiving additional induction asparaginase (P 5 2.7 3 10 -4 ), non-black race (P 5 8.7 3 10 -13 for whites and P 5 2.6 3 10 -7 for Hispanics), older age (P 5 1.4 3 10 -6 ), and higher BMI (P 5 2.9 3 10 -3 ). Race group accounted for 7.2% of the variability in ALT levels ( Table 3) . Focusing on the National Cancer Institute's common toxicity criteria (CTCAE) categories of ALT toxicity, Total XVI patients had more grade 2-3 ALT elevations compared to Total XV patients (P 5 5.8 3 10 -3 , Figure S2a ). To identify genetic variants associated with postinduction ALT levels in the SJCRH discovery cohort, we used a multivariate linear regression model including treatment protocol, use of additional asparaginase doses, percentage of Northern European ancestry, West African ancestry, and Native American ancestry, age, and BMI percentile as covariates along with genotypes. The strongest association (P 5 2.5 3 10 -8 ) with ALT levels was with the PNPLA3 rs738409 (C>G) I148M variant ( Figure 2a , Table 4 ), a missense polymorphism known as a quantitative trait locus (QTL) for ALT in the general population. 10 The median ALT level for patients of C/C, G/C, and G/G diplotypes was 35, 45 , and 58 IU/L, respectively. When ALT was translated into CTCAE categories of ALT toxicity, the frequency of higher ALT grade (grade >2) was 2.6%, 3.9%, and 5.3%, respectively, among patients of C/C, G/C, and G/G diplotypes ( Figure S2b) . The association of PNPLA3 rs738409 with ALT treated as a continuous variable was observed in both Total XV (P 5 5.5 3 10 -6 ) and Total XVI (P 5 2.7 3 10 -4 ) ( Figure S3a) , and differed within race groups (Figure 3a, Figure S3b) . Interestingly, the minor allele frequency (MAF) of PNPLA3 rs738409 was highest among Hispanics (44.2%), followed by whites (23.1%), and lowest in blacks (13.1%) in our cohort, as observed in previous studies, 11 and followed the same trend as their postinduction ALT levels ( Figure 3b) . Principal component analysis (PCA) within each race group did not uncover any stratification among the patients carrying the different PNPLA3 rs738409 genotypes ( Figure S4a-c) .
Because the impact of PNPLA3 rs738409 on ALT elevation differed by race (Figure 3a, Figure S3b) , and because ALT levels differed among races in the same direction that the PNPLA3 rs738409 MAF did (Figure 3b) , we questioned whether the association between race and ALT elevation was accounted for mostly by this variant. After adding PNPLA3 rs738409 genotype to a multivariate analysis for determinants of ALT levels, the PNPLA3 single nucleotide polymorphism (SNP) accounted for 3.8% of ALT variability, and race group still remained an important risk factor (P 5 3.7 3 10 -11 , 6.6 3 10 -5 , and 2.0 3 10 -3 for whites, Hispanics, and others vs. blacks, respectively), and explained 5.3% of the variability in ALT elevation after incorporating the PNPLA3 SNP (Table 3) . Therefore, we performed three separate ancestry-specific genome-wide association studies (GWASs) among whites, blacks, and Hispanics (Tables S2-S4) to identify additional possible race-specific genetic determinants of ALT, including the percentage of West African and Native American ancestries as covariates in the GWASs within blacks and Hispanics, respectively. Two variants, PIGV rs12748152 and GREB1 rs149940960, had P values approaching genomewide significance and only in blacks (P 5 1.3 3 10 -8 and 2.0 3 10 -8 respectively, Figures 2b, 3c,d) . Coincidentally, the three subjects harboring the minor allele of GREB1 rs149940960 also No discrete ALT levels were available for COG AALL0232 patients.
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had the minor allele of PIGV rs12748152. Both variants were associated with lower ALT only in blacks (P 5 0.14 in whites and P 5 0.59 in Hispanics for PIGV rs12748152, Figure 3c ; the GREB1 rs149940960 was detected in blacks only). The PIGV rs12748152 had a higher MAF in whites (7.1%) than blacks (1.8%) and Hispanics (0.8%), whereas the GREB1 rs149940960 had MAF 5 1.7% in blacks, in accordance with the general population frequency (1000 Genomes Project). In addition, when race structure was calculated with PCA and the first five principal components were used as covariates in each race-specific GWAS, the top SNPs and P values for association with ALT did not change substantially (Tables S2-S4) , and PCA within blacks did not uncover any stratification among the patients carrying the different PIGV rs12748152 genotypes ( Figure S4d ). PNPLA3 rs6006460 (G>T) was previously reported to protect blacks from the development of nonalcoholic fatty liver disease (NAFLD). 12 The PNPLA3 rs6006460 minor allele was among the protective variants in our discovery cohort as well (P 5 3.2 3 10 -3 , Figure S5a ), and the effect was significant when restricted only to blacks in our cohort (P 5 0.041, Figure S5b ). The frequency of this protective variant was highest in the blacks of our cohort (MAF 5 11%) and thus may have counteracted the adverse effects of carrying the risk allele of PNPLA3 rs738409, therefore helping to explain why PNPLA3 rs738409 was not significantly associated with increased ALT among blacks (P 5 0.20, Figure 3a , Figure S3b ). In blacks, the PNPLA3 Table S1 ).
rs738409 explained 1.3% of the variability in ALT level (P 5 0.065), while PNPLA3 rs6006460 explained another 5.8% (P 5 0.014). In contrast, among non-blacks in the discovery cohort PNPLA3 rs738409 explained 4.2% of the variability, whereas PNPLA3 rs6006460 added only 1.2% (P < 2.2 3 10 -16 for both). A total of 109 variants within the PNPLA3 gene were found in the SJCRH cohort, 65 of which had nominal P values of < 0.05 for their association with ALT, with 61/65 having the minor allele associated with higher ALT (Table S5) . A gene-level GWAS including the same covariates as the single SNP GWAS (protocol, asparaginase dosage, percent ancestry, age, and BMI percentile) identified PNPLA3 as an overall detrimental gene for ALT levels (P 5 0.0093), reflecting the collective impact of PNPLA3 variants.
In the replication cohort AALL0232, ALT elevation was classified into grade >2 vs. grade 2. Accounting for the significant covariates of age, race, gender, and the induction steroid (Table S6) , PNPLA3 rs738409 was associated with the frequency of grade >2 ALT elevations in the entire AALL0232 cohort (P 5 0.024) ( Figure S6 ) and when the analysis was limited to Hispanics (P 5 0.01), thus independently replicating the polymorphism's association.
Because the PNPLA3 variant rs738409 has been previously linked to elevated ALT levels and to the development of hepatic The effect size refers to the exponent of the beta coefficient estimated from the linear regression. Numbers in parentheses indicate 95% confidence interval.
b Whites were defined as having > 90% Northern European ancestry, blacks as having > 70% West African ancestry, Hispanics as having Native American ancestry greater than 10% and Native American ancestry was greater than their percent African ancestry, and others were those whose ancestry was outside the above boundaries. steatosis in the general population, 13 its association with elevated ALT after remission induction therapy suggested that asparaginase may influence blood ALT levels through dysregulation of hepatic lipids. We confirmed that PEGylated E. coli asparaginase caused hepatic steatosis in mice, as evidenced by a doubling in Oil-red O (ORO) staining in livers of mice treated with the drug compared to control ( Figure S7 ).
DISCUSSION
Patients with ALL are at increased risk for the development of toxicities, including hepatotoxicity, which is partly reflected by elevated serum aminotransferase levels. 3 Our objectives were to use a genome-wide approach to determine inherited variation associated with ALT elevation among a racially diverse set of pediatric patients with ALL at a uniform timepoint (the end of remission induction), adjusting for clinical and other covariates potentially associated with increased ALT levels. Although many ALL medications can contribute to elevations in serum ALT, our multivariate analysis suggested that elevated postinduction chemotherapy ALT levels were linked to asparaginase exposure (Figure 1a,b, Table 3 ). Patients on Total XVI (who all received PEGylated E. coli asparaginase) had higher ALT levels compared to the Total XV patients (who all received the less potent native E. coli asparaginase) (P 5 0.041, Figure 1a , Table 3 ), despite the fact that patients on Total XV received preinduction high-dose methotrexate, whereas those on Total XVI did not ( Table 1 , Figure S9 ), suggesting an effect of asparaginase preparation on hepatotoxicity. Moreover, those who received additional asparaginase during induction had higher ALT levels compared to those that did not receive additional asparaginase (P 5 2.7 3 10 -4 , Figure 1b, Table 3 ). Interestingly, serum bilirubin at the end of induction did not differ by asparaginase exposure (data not shown). Adjusting for treatment, host-related covariates (e.g., age, BMI percentile) and ancestry, we found that the PNPLA3 rs738409 I148M variant associated with higher ALT levels. This is the identical genetic variant that has previously been linked to ALT elevation in the general population, 10 NAFLD, 12, 14, 15 NAFLD severity, 16 and hepatic fibrosis 15 in genome-wide studies. The effect on NAFLD susceptibility and severity was confirmed by meta-analyses. 17 This variant was also associated with poor chronic hepatitis C treatment response, 18 hepatocellular carcinoma, 19 and insulin resistance. 20 Overall in the discovery cohort of 715 patients, the median increase in ALT was 12 IU/L, or 33.3% of the median of the major allele homozygous (C/C) group, for each minor allele of PNPLA3 (P 5 0.032), compared to a 6.0% increase for each allele observed in the general population, Alleles were assigned as major or minor ones based on their frequency in the cohort of our study. The effect size refers to the exponent of the beta coefficient of the minor allele estimated from the linear regression in PLINK. An effect size greater than 1 indicates the minor allele is the risk allele.
suggesting that the effect of the variant is amplified during ALL therapy, and consistent with larger effect sizes for pharmacogenetic traits. 21 Because of hepatic infiltration of ALL at diagnosis and the prolonged use of potentially hepatotoxic chemotherapy, there is no optimal time to measure "baseline" ALT in ALL. 22 We did examine ALT levels at diagnosis within the SJCRH cohort and showed that serum ALT levels were lower at diagnosis than at end-of-induction (P < 2.2 3 10 -16 , paired t-test, Figure S8 , Table 2 ), and that PNPLA3 rs738409 remains a significant risk factor (P 5 4.4 3 10 -6 ) for postinduction ALT elevation even after including diagnostic ALT as a covariate.
Patatin-like phospholipase domain containing protein 3 (PNPLA3 or adiponutrin) is a member of the family of patatinlike lipolytic enzymes involved in triacylglycerol metabolism and signaling. 23 It has been shown that substituting methionine for isoleucine at position 148 markedly compromised the catalytic velocity of PNPLA3. 24 This is reflected in knock-in mice studies suggesting that the PNPLA3 I148M variant leads to an increased risk of hepatotoxicity due to accumulation of PNPLA3 on lipid droplets in the liver, a reduction in triglyceride hydrolase activity, and accumulation of hepatic triglycerides. 25 Our finding that the top-ranked genetic variation associated with drug-induced liver dysfunction after ALL therapy is identical to one of the top genetic risk factors for constitutive liver dysfunction is remarkable, and has implications for the field of pharmacogenetics and its use to predict drug toxicities.
We confirmed that asparaginase exposure in mice indeed led to an accumulation of hepatic lipids and neutral triglycerides ( Figure S7) . The results suggest that the mechanism of asparaginase-induced hepatotoxicity may be similar to that of hepatic steatosis, and may be attenuated by therapies that can mitigate hepatic triglyceride accumulation. These results may have particular implications for adults with ALL, in whom hepatotoxicity is common. 26 Interestingly, an early postmortem study from 31 pediatric ALL patients that received native E. coli asparaginase found that 87% had developed steatosis after exposure to asparaginase. 27 We observed that ALT was higher ( Table 3, Table S6 ) in those with ancestry indicating Hispanic status or whites than in blacks, as others have reported.
11 Differences in the risk allele frequency of the PNPLA3 rs738409 variant mirrored the differences in ALT among race groups (Figure 3b) , although this variant did not reach statistical significance in blacks or Hispanics (Figure 3a, Figure S3b) , likely due to relatively low power because of small sample sizes for non-whites (with an effect size of 1.36 for the rs738409 variant, our power to detect a significant effect in separate GWASs of blacks and Hispanics was only 0.32 and 0.37, respectively). Although the PNPLA3 rs738409 variant accounted for some variability in ALT across race groups, race remained a significant risk factor for ALT even after accounting for PNPLA3 rs738409.
We found that some of the additional association of race with ALT might be due to other genetic variants. For example, black patients carrying the PIGV rs12748152 and GREB1 rs149940960 variants had lower ALT levels compared to noncarriers (Figure 3c,d , Table S3 ). PIGV rs12748152 is an expression quantitative trait locus (eQTL) for PIGV, ARID1A, and ZDHHC18, 28, 29 and is also a QTL for cholesterol and triglycerides levels, 30 whereas GREB1 rs149940960 is in the 3 0 untranslated region (3 0 -UTR) of GREB1, which regulates circulating levels of chemoattractant protein-1 (CCL2) and insulin-like growth factor binding protein 3 (IGFBF-3) . 31 High levels of the latter are associated with adiposity and insulin resistance, 32 while the former is a cytokine that recruits immune cells into damaged areas of the liver. 33 Reports suggest that infiltrating immune cells directly kill distressed hepatocytes overloaded with triglycerides. Preventing this infiltration with nuclear factor kappa B (NF-jB) inhibitors may be another possible avenue of intervention. 34 Although it has not been implicated in NAFLD, PIGV is involved in the biosynthesis of glycosylphosphatidylinositol. The PIGV rs12748152 variant explained 26.6% of the variability in ALT levels among black patients. However, there was no significant association in those with low West African ancestry (P 5 0.27), and the variant was actually present at a lower frequency among blacks than other race groups (MAF 5 2.0% in blacks, 13.3% in non-blacks). Limitations of these speculations lie in the small sample size of blacks in our cohort and low MAF of these genetic variants among them.
Although we think asparaginase was the most likely cause of postinduction ALT elevations in this study, we acknowledge that other elements of ALL induction therapy can also cause increases in ALT. Interestingly, high-dose methotrexate is well known to cause acute elevations in ALT, 35 but this was unlikely to have contributed to the end-of-induction ALT (which was measured 42-46 days after a single dose of methotrexate for Total XV), and because high-dose methotrexate was used prior to induction only in Total XV, not Total XVI (Table 1, Figure S9) , and yet ALT was higher in patients enrolled on Total XVI compared to Total XV (Figure 1a) . Likewise, although thiopurines can cause elevations in ALT, they are more prominent with mercaptopurine (used in Total XV) than with thioguanine (used in Total XVI) ( Table 1) , 36, 37 and thus unlikely to explain the higher ALT on Total XVI compared to Total XV. The use of PEGasparaginase at 3,000 units/m 2 on Total XVI results in much higher and more prolonged serum asparaginase concentrations than the doses of native E. coli asparaginase that we used on Total XV. 38 Most tellingly, in both Total XV and Total XVI, ALT was higher in the 25% of patients who required extra doses of asparaginase due to high MRD during induction therapy than it was in those who did not receive extra doses (Figure 1b) .
The association of PNPLA3 rs738409 with ALT after induction therapy was replicated in the COG AALL0232 protocol. The replication is somewhat remarkable in that there were several important factors that differed between the discovery and replication cohorts. First, patients on AALL0232 were older than those in the SJCRH discovery cohort (Table 2) , and, as expected, exhibited higher ALT grades. Second, discrete ALT values were not available for the AALL0232 cohort, only CTCAE grades; and very few cases of grades 1 and 2 ALT elevation were recorded. Thus, we used linear regression in the discovery cohort but used case (grade >2)-control (grade 2) logistic regression for the replication cohort ( Figure S6) . Finally, BMI was not available for patients in AALL0232. Despite these differences, the effect of PNPLA3 rs738409 variant was still replicated.
In summary, we have identified that elevated postinduction chemotherapy ALT levels were likely due primarily to asparaginase, and we found that the same PNPLA3 I148M variant that was previously shown to be the most important determinant of NAFLD in a general population of adults is associated with druginduced increases in serum ALT. Together, our genetic data from patients with ALL and our preclinical data in mice suggest that hepatotoxicity caused by ALL remission-induction chemotherapy may be mediated by induction of fatty liver and that the toxicity can be modulated by inherited germline polymorphisms that affect hepatic triglyceride homeostasis.
METHODS Patients
The discovery cohort consisted of patients enrolled on SJCRH protocols Total XV 39 (n 5 373, ClinicalTrials.gov identifier: NCT00137111) and Total XVI 40 (n 5 342, ClinicalTrials.gov identifier: NCT00549848) for newly diagnosed ALL. The replication cohort consisted of children with newly diagnosed ALL who were treated on the COG AALL0232 protocol (N 5 2,285, ClinicalTrials.gov identifier: NCT00075725) for highrisk B-precursor ALL. Patients included in the genetic association analyses represented 85% (n 5 715 of 840) of patients in the SJCRH primary clinical trials, and 80% (n 5 2285 of 2868) of participants in the COG primary clinical trial ( Figure S1 ).
Informed consent from the parents or guardians or patients, and assent from the patients, where appropriate, were obtained according to guidelines used at the Institutional Review Boards of the participating institutions. The COG AALL0232 protocol was also approved by the National Cancer Institute.
For the SJCRH cohort, ALT values were graded using CTCAE v. 3.0. 41 ALT values between 1.02.5-fold of normal upper limit were assigned as grade 1, between 2.55.0-fold as grade 2, between 5.020.0-fold as grade 3, and >20.0-fold as grade 4. Patient BMI at the time of ALT sample collection was calculated and BMI percentile was determined as described previously with obesity defined as 95th percentile. 42 For the COG AALL0232 cohort, ALT values were graded using the CTCAE v. 4.0. ALT values between 1.03.0-fold of normal upper limit were assigned as grade 1, between 3.05.0-fold as grade 2, between 5.0 20.0 fold as grade 3, and >20.0-fold as grade 4.
Treatment
During induction therapy, patients enrolled on the SJCRH Total XV or Total XVI protocols received asparaginase, prednisone, vincristine, daunorubicin, cyclophosphamide, cytarabine, and thiopurine (Table 1, Figure S9) . 39, 40 Total XV patients received native E. coli asparaginase (Elspar) at 10,000 units/m 2 IM, three times weekly for six doses and Total XVI patients received a single dose of PEGylated E. coli asparaginase (Oncaspar) at 3,000 units/m 2 IV. Patients on Total XV with day 19 MRD 5% received three additional doses of native E. coli asparaginase over a week's period, and patients on Total XVI with day 15 MRD 1% received an additional dose of PEGylated E. coli asparaginase (Table 1, Figure S9 ). Postinduction samples for ALT and total bilirubin measurement were drawn on day 46 (Total XV) and on day 42 (Total XVI) from the start of remission induction therapy, regardless of clinical suspicion of hepatotoxicity ( Figure S9 ). ALT and total bilirubin were also measured at diagnosis (preinduction therapy), before the patients were exposed to methotrexate or asparaginase ( Figure S9) .
During induction therapy, patients enrolled on COG AALL0232 received vincristine, daunorubicin, dexamethasone or prednisone, and PEGylated E. coli asparaginase. 43 Patients with day 29 MRD between 1% and 25% received extended induction consisting of additional doses of vincristine, daunorubicin, dexamethasone or prednisone, and PEGylated E. coli asparaginase. During consolidation, patients received cytarabine, vincristine, cyclophosphamide, mercaptopurine, and PEGylated E. coli asparaginase ( Table S7) . Measurement of ALT levels was a required observation on COG AALL0232 on day 1 of induction and at the start of consolidation and was performed at other times at the discretion of the treating physician. Sites were required to report all grade 3 and higher ALT elevation.
Genotyping
Among patients with evaluable postinduction ALT data, germline DNA was genotyped using the Exome-24 BeadChip (Illumina, San Diego, CA) (686 patients in SJCRH cohort and 2,285 in AALL0232 trial) and either the Affymetrix Genome-Wide Human SNP Array 6.0 or the Affymetrix Human Mapping 500K Array Set (715 in SJCRH cohort and 2,285 for AALL0232 trial), as described previously. 44 MaCH-Admix (http://www.unc.edu/yunmli/MaCH-Admix) was used to impute the remaining untyped SNPs using the 1000 Genomes Project (http://www. 1000genomes.org) as described elsewhere. 45, 46 Germline DNA from 552 patients from the SJCRH cohort was also subjected to whole exome sequencing. For this, genomic libraries were prepared using the NimbleGen SeqCap EZ Exome Enrichment Kit v. 2.0 (Roche NimbleGen, Madison, WI) and sequencing was performed using the HiSeq 2000 Sequencing System (Illumina). The Hardy-Weinberg equilibrium (HWE) test was performed using PLINK on SNPs with an MAF 1% and among patients of European ancestry. SNPs with genotyping call rates < 95% and SNPs that were not in HWE (P < 0.001) were excluded from the association analysis ( Figure S1 ).
Genetic ancestry
The genetic ancestry of patients was determined using STRUCTURE (http://pritchardlab.stanford.edu/structure.html) as previously described, 47 and percent ancestry was treated as a continuous variable or used to assign patients to race groups: whites were defined as having >90% Northern European ancestry, blacks as having >70% West African ancestry, Hispanics as having Native American ancestry >10% and greater than their African ancestry percentage, Asians as having >90% East Asian ancestry, and others as those whose ancestry was outside the above boundaries. In the SJCRH cohort, patients of Asian ancestry were grouped with others due to their small sample size.
Preclinical in vivo asparaginase-induced hepatotoxicity studies Male Balb/cJ mice (4-week-old) (Jackson Laboratories, Bar Harbor, ME) received 1,500 IU/kg of PEGylated E. coli asparaginase by intraperitoneal injection twice weekly for 6 weeks. Livers were collected at the end of the experiment and snap-frozen in liquid nitrogen. Frozen livers were immersed in OCT media and 4 lm sections were stained with Oil-red O. The staining intensity was quantified using the Aperio Image analysis system (Aperio, Vista, CA). Three 1-mm 2 square regions for each sample were analyzed and the number of strongly positive pixels in the regions was used to compare experimental and control samples. All experiments involving the use of mice were approved by the Institutional Animal Care and Use Committee (IACUC) of St. Jude Children's Research Hospital. Mice were housed in an American Association of Laboratory Animal Care-accredited facility. The study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH).
Data analysis
Univariate and multivariate linear regression was performed using a general linear model with R statistical software (v. 2.13.2, Vienna, Austria) to identify clinical risk factors associated with postinduction ALT levels as a continuous variable. For the COG AALL0232 replication cohort, associations between clinical risk factors and the frequency of grade >2 hepatotoxicity were determined using Fisher's exact test in R. The genome-wide association analysis between SNP genotypes and ALT was performed in PLINK 1.9 (https://www.cog-genomics.org/plink2) using linear or logistic regression as appropriate, adjusting for significant covariates and assuming an additive genetic model. 48 Within each race group defined above (whites, blacks, and Hispanics), the first five principal components were calculated using GCTA v. 1.26.0 (http://cnsgenomics. com/software/gcta/) with genotype data acquired from the Affymetrix arrays. Gene-level association was done using the sequence kernel association test (SKAT) as implemented by PLINK/SEQ (https://atgu.mgh. harvard.edu/plinkseq/). Linkage disequilibrium based variant pruning was performed using PLINK. To assess the proportion of variability in ALT accounted for by specific genomic variants, a general linear model was used.
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